Business Description
Compare
Compare
Traded in other countries / regions
506128.India IPO Date
2009-09-15Description
Parnax Lab Ltd is principally engaged in the manufacturing and export of Pharmaceutical Formulations. Its product categories include Pharmaceuticals; Cosmetics; Herbal and Nutraceuticals. The company is developing and delivering Oral Formulations such as Cough Expectorants, Antacids, Anti-Histamines, Multi-Vitamins, Enzyme Preparations, Pediatric Formulations, Special Formulations for Geriatrics, Highly Viscous Products, Suspensions, and others.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.04 | |||||
| Equity-to-Asset | 0.43 | |||||
| Debt-to-Equity | 0.88 | |||||
| Debt-to-EBITDA | 2.54 | |||||
| Interest Coverage | 3.17 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.42 | |||||
| Beneish M-Score | -2.87 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.6 | |||||
| 3-Year EBITDA Growth Rate | 37.9 | |||||
| 3-Year Book Growth Rate | 12 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.35 | |||||
| 9-Day RSI | 35.24 | |||||
| 14-Day RSI | 43.62 | |||||
| 6-1 Month Momentum % | 36.22 | |||||
| 12-1 Month Momentum % | 70.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.99 | |||||
| Quick Ratio | 0.6 | |||||
| Cash Ratio | 0.03 | |||||
| Days Inventory | 66.01 | |||||
| Days Sales Outstanding | 58.29 | |||||
| Days Payable | 43.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.5 | |||||
| Shareholder Yield % | 5.27 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 30 | |||||
| Operating Margin % | 8.77 | |||||
| Net Margin % | 4.81 | |||||
| FCF Margin % | 5.26 | |||||
| ROE % | 14.12 | |||||
| ROA % | 5.93 | |||||
| ROIC % | 9.39 | |||||
| ROC (Joel Greenblatt) % | 14.08 | |||||
| ROCE % | 19.72 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 16.11 | |||||
| PE Ratio without NRI | 15.8 | |||||
| Shiller PE Ratio | 25.13 | |||||
| Price-to-Owner-Earnings | 35.34 | |||||
| PEG Ratio | 1.05 | |||||
| PS Ratio | 0.76 | |||||
| PB Ratio | 2.05 | |||||
| Price-to-Tangible-Book | 2.06 | |||||
| Price-to-Free-Cash-Flow | 13.82 | |||||
| Price-to-Operating-Cash-Flow | 6.37 | |||||
| EV-to-EBIT | 11.77 | |||||
| EV-to-EBITDA | 8.38 | |||||
| EV-to-Revenue | 1.06 | |||||
| EV-to-FCF | 20.24 | |||||
| Price-to-DCF (Earnings Based) | 1.7 | |||||
| Price-to-DCF (FCF Based) | 1.49 | |||||
| Price-to-Median-PS-Value | 2.09 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.75 | |||||
| Earnings Yield (Greenblatt) % | 8.5 | |||||
| FCF Yield % | 6.97 | |||||
| Forward Rate of Return (Yacktman) % | 14.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Parnax Lab Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 1,832.487 | ||
| EPS (TTM) (₹) | 7.466 | ||
| Beta | 0.7 | ||
| Volatility % | 63.49 | ||
| 14-Day RSI | 43.62 | ||
| 14-Day ATR (₹) | 8.924408 | ||
| 20-Day SMA (₹) | 135.035 | ||
| 12-1 Month Momentum % | 70.22 | ||
| 52-Week Range (₹) | 55 - 167.9 | ||
| Shares Outstanding (Mil) | 11.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Parnax Lab Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Parnax Lab Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Parnax Lab Ltd Frequently Asked Questions
What is Parnax Lab Ltd(BOM:506128)'s stock price today?
The current price of BOM:506128 is ₹120.25. The 52 week high of BOM:506128 is ₹167.90 and 52 week low is ₹55.00.
When is next earnings date of Parnax Lab Ltd(BOM:506128)?
The next earnings date of Parnax Lab Ltd(BOM:506128) is .
Does Parnax Lab Ltd(BOM:506128) pay dividends? If so, how much?
Parnax Lab Ltd(BOM:506128) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers